Delving into the Latest Updates on Olmesartan Medoxomil with Synapse

A 74‐year‐old man with decreased appetite, weight, and heartburn was referred to our hospital. His medications included olmesartan. Esophagogastroduodenoscopy (EGD) revealed antral‐dominant erosive gastritis and nodular mucosa. A gastric biopsy revealed inflammatory cell infiltration. The serum anti‐Helicobacter pylori immunoglobulin G antibody test result was negative. Famotidine was ineffective in relieving his symptoms, and esomeprazole failed to prevent overt gastric bleeding, which required endoscopic hemostasis. The working diagnosis was drug‐induced gastritis, particularly olmesartan‐induced gastritis. His appetite loss started to improve within a week of olmesartan withdrawal. The erosions healed on EGD 2 months later. Over the next 10 months, he remained in his usual state until olmesartan was inadvertently administered. Subsequent EGD revealed a mild gastritis relapse. We diagnosed olmesartan‐induced gastritis and discontinued olmesartan treatment. Mucosal healing was confirmed by EGD 1 year later. Olmesartan is known to cause angiotensin II receptor blocker‐induced enteropathy. Although angiotensin II receptor blocker‐induced enteropathy affects the stomach, angiotensin II receptor blocker‐induced gastritis without lower gastrointestinal symptoms is rare. The characteristic endoscopic appearance may provide a clue to the correct diagnosis.

01 Jun 2025·BIORESOURCE TECHNOLOGY

Aerobic biodegradation of micropollutants by nitrifiers and heterotrophs: Changes in biodegradation rate constant depending on levels of growth substrates and microbial activities

Article

Author: Wang, Jinhua ; Lee, Sungman ; Son, Heejong ; Lee, Jihea ; Kim, Young Mo ; Heo, Seongbong

This study investigated how the biodegradation rate constant (k_bio) of 11 micropollutants (MPs) responded to changes in the concentrations of growth substrates and microbial activities while considering the predominant microbial degraders of MPs. Metformin, losartan, valsartan, and cimetidine (group A) were biodegraded predominantly by nitrifiers. MPs of group A showed a positive correlation with k_bio and nitrifying activity, while a negative correlation was observed with the initial concentration of ammonium, possibly due to competitive inhibition. Atenolol, caffeine, and naproxen (group B) were biodegraded predominantly by heterotrophs, with k_bio remaining stable despite changes in organic matter concentration or heterotrophic activity. Olmesartan, candesartan, diclofenac, and sulfamethoxazole (group C) showed low k_bio regardless of growth substrate concentration and microbial activity, which could be attributed to their chemical structures. These findings suggest that the k_bio of MPs in WWTPs could respond differently to growth substrate concentration and microbial activity depending on their predominant degraders.

01 Jun 2025·LIFE SCIENCES

Olmesartan attenuates doxorubicin-elicited testicular toxicity: The interaction between sirtuin-1, HMGB1/NLRP3 inflammasome/gasdermin D signaling, and AMPK/mTOR-driven autophagy

Article

Author: Atia, Hanan Abdelmawgoud ; Khalifa, Amany M ; Elariny, Hemat A ; Kabel, Ahmed M ; Elkady, Mennatallah A ; Abdallah, Marwa H ; Abd Elmaaboud, Maaly A

BACKGROUND:

In the recent years, there has been an increased incidence of testicular toxicity associated with doxorubicin (DOX) use in cancer therapy. The mechanisms of this adverse effect may include induction of oxidative stress with augmentation of the inflammatory and the apoptotic signals in the testicular tissues. The ongoing research is directed towards the exploration of new agents that are capable of overcoming this health problem. This study was a trial to evaluate the efficacy of Olmesartan as a protective agent against DOX-induced testicular dysfunction in male rats.

MATERIALS AND METHODS:

Forty adult male Sprague-Dawley rats were divided into control group, DOX-injected group, and three DOX-injected groups treated with olmesartan at 3 dose levels (1, 5, and 10 mg/kg/day). The effect of the different treatments was assessed at the biochemical and the morphological levels.

KEY FINDINGS:

Olmesartan administered to DOX-treated rats induced dose-dependent restoration of the testicular weight and functions, normalization of the hormonal profile, augmentation of the antioxidant defenses, and potentiation of AMPK/mTOR-driven autophagy in comparison to rats treated with DOX alone. These effects were accompanied with a dose-dependent significant mitigation of the cellular events related to pyroptosis and inflammation and a significant amelioration of the testicular morphological changes induced by DOX.

SIGNIFICANCE:

Olmesartan may represent a promising therapy for DOX-elicited testicular dysfunction, possibly via dose-dependent antioxidant, anti-pyroptotic, anti-inflammatory, and autophagy enhancing effects.

19

News (Medical) associated with Olmesartan Medoxomil

15 Nov 2024

·www.businesswire.com

PCE Automation Acquires Olmec-UK

BECCLES, England--( BUSINESS WIRE )--Automation solutions provider, PCE Automation Ltd completes its second acquisition in just two years, with north Lincolnshire-based vision inspection and web conversion provider, Olmec-UK being the latest addition to its expanding portfolio. The acquisition was a strategic choice, allowing PCE Automation to strengthen its existing presence within the Life Science sector by bringing vision inspection and web conversion capabilities into its offering. PCE plans to diversify into new market segments within the medical device arena, such as Advanced Wound Care, Ostomy and Continence Care, Drug Delivery Systems, and Ocular. James Cook, CEO of PCE Automation said, “The acquisition of Olmec is a key milestone in delivering on our strategic business vision and goal of being a one-stop shop for medical clients. It will allow us to offer a full turnkey solution for our customers, helping to reduce complexity, time to market, friction costs, CapEx, and downtime throughout the full value chain.” The acquisition finalised in November 2024 following an 18-month process and is set to bring a 25% growth in sales orders, as well as providing PCE with a sales hub for the north of the UK. The north Lincolnshire location will be PCE’s fourth site, working alongside the existing sites in Beccles and Lutterworth, and the newly introduced Dublin site, following the acquisition of Adapt Engineering in 2023. The move also brings benefits to Olmec, from increased resources to full automation line capabilities. Robert Pounder, Managing Director of Olmec-UK said, “The two companies are very well aligned in terms of culture and delivering an excellent customer experience. In joining PCE Automation, we’re tapping into a wealth of resources and expertise that will help us to provide an enhanced experience for our customers. “Together with PCE, we look forward to delivering innovative, cutting-edge solutions that will make a real difference to Life Science manufacturing across PCE’s global automation footprint." About PCE Automation PCE Automation is a UK-based automation solutions provider with a global footprint. Specialising in the Life Science sector, PCE provides solutions for clients across the world. About Olmec-UK Olmec-UK is a vision inspection and web conversion company based in north Lincolnshire in the UK. Olmec has been serving a multitude of markets since 2006.

Acquisition

06 Nov 2024

·pharma.economictimes.indiatimes.com

Paracetamol to PAN-D: CDSCO finds over 50 sub-standard drugs. Check full list of medicines

New Delhi: The Central Drugs Standard Control Organisation ( CDSCO ) has identified over 50 drugs which have failed in the drug test. In its latest report, the controller said 50 drugs including Paracetamol are "not of standard quality" (NSQ). The report has also flagged calcium and vitamin D3 supplements, anti-diabetes pills, and high blood pressure medicines. Paracetamol tablets from Karnataka Antibiotics & Pharmaceuticals Ltd were specifically mentioned for quality concerns. The report listed a total of 48 drugs in the NSQ category, including a Gauze Roll Non Sterile Roller Bandage. NSQ alerts come from monthly random sampling conducted by state drug officers. Some of the medicines were produced by companies like Hetero Drugs, Alkem Laboratories, Hindustan Antibiotics Limited (HAL), Karnataka Antibiotics & Pharmaceuticals Ltd, Meg Lifesciences, and Pure & Cure Healthcare. Additionally, the CDSCO shared another list that features five more drugs that failed quality tests. The pharmaceutical companies denied responsibility for these drugs. They claim they are "spurious," and one response from a company stated, "The actual manufacturer (as per label claim) has informed that the impugned batch of the product has not been manufactured by them and that it is a spurious drug. The product is purported to be spurious; however, the same is subjected to outcome of investigation." CDSCO NSQ Test: Full list of drugs and their manufacturers Here is the list of drugs that failed the CDSCO test along with the manufacturers: Amoxicillin And Potassium Clavulanate Tablets IP (Clavam 625) - M/s. Alkem Health Science Amoxicillin & Potassium Clavulanate Tablets (Mexclav 625) - M/s. Meg Lifesciences Calcium And Vitamin D3 Tablets IP (Shelcal 500) - M/s. Pure & Cure Healthcare Pvt. Ltd. Metformin Hydrochloride Sustained-release Tablets IP (Glycimet-SR-500) - M/s. Scott-Edil Pharmacia Ltd. Vitamin B Complex with Vitamin C Softgels - M/s. Asoj Soft Caps Pvt. Ltd. Rifmin 550 (Rifaximin Tablets 550 mg) - M/s. Legen Healthcare Pantoprazole Gastro-Resistant and Domperidone Prolonged-Release Capsules IP (Pan - D) - M/s. Alkem Health Science Paracetamol Tablets IP 500 mg - M/s. Karnataka Antibiotics and Pharmaceuticals Ltd. Montair LC Kid (Montelukast Sodium & Levocetirizine Hydrochloride Dispersible Tablets) - M/s. Pure & Cure Healthcare Pvt. Ltd. Compound Sodium Lactate Injection IP (Ringer Lactate Solution for Injection) (RL 500 ml) - M/s. Vision Parenteral Pvt. Ltd. Fexofenadine Hydrochloride Tablets IP 120 mg - M/s. Maxtar Bio-Genics Laxnorm Solution (Lactulose Solution USP) - M/s. Athens Life Sciences Heparin Sodium Injection 5000 Units (Hostranil Injection) - M/s. Health Biotech Ltd. Buflam Forte Suspension (Ibuprofen & Paracetamol Oral Suspension) - M/s. Ornate Pharma Pvt. Ltd. Cepodem XP 50 Dry Suspension (Cefpodoxime Proxetil and Potassium Clavulanate Oral Suspension) - M/s. Hetero Labs Limited Nimesulide, Paracetamol and Chlorzoxazone Tablets (NICIP MR) - M/s. HSN International Rolled Gauze (Non-Sterilized) - M/s. Blazon India Ciprofloxacin Tablets IP 500 mg (Ocif-500) - M/s. Ornate Labs Pvt. Ltd. Nimesulide, Phenylephrine Hydrochloride & Levocetirizine Dihydrochloride Tablets (Nunim-Cold) - M/s. Unispeed Pharmaceuticals Pvt. Ltd. Adrenaline Injection IP Sterile 1 ml - M/s. Alves Healthcare Pvt. Ltd. Compound Sodium Lactate Injection IP (Ringer Lactate Solution for Injection) RL 500ml - M/s. Vision Parentral Pvt. Ltd. Vingel XL Pro Gel (Diclofenac Diethylamine, Linseed Oil, Methyl Salicylate, and Menthol Gel) - M/s. Universal Twin Labs Atropine Sulphate Injection IP 2 ml - M/s. Nandani Medical Laboratories Pvt. Ltd. Cefoperazone & Sulbactam For Injection (Todaycef 1.5 G) - M/s. Daxin Pharmaceuticals Pvt. Ltd. Heparin Sodium Injection IP 25000 IU / 5ml - M/s. Scott-Edil Pharmacia Ltd. Cefepime & Tazobactam for Injection (Crupime - TZ Kid Injection) - M/s. Cosmas Research Lab. Ltd. Atropine Sulphate Injection IP (Atropine Sulphate) - M/s. Priya Pharmaceuticals Salbutamol, Bromhexine HCI, Guaifenesin and Menthol Syrup (Acozil Expectorant) - M/s. Antila Lifesciences Pvt. Ltd. Diclofenac Sodium IP - M/s. Sara Exports Ltd. Escitalopram and Clonazepam Tablets IP (Klozaps-ES Tablets) - M/s. Digital Vision Phenytoin Sodium Injection USP - M/s. Health Biotech Ltd. Paracetamol, Phenylephrine Hydrochloride and Cetirizine Hydrochloride Suspension (Cethel Cold DS Suspension) - M/s. Win Cure Pharma Calcium 500 mg with Vitamin D3 250 IU Tablets IP - M/s. Life Max Cancer Laboratories Amoxycillin and Potassium Clavulanate Tablets IP 625 mg (Renamega- CV 625) - M/s. Malik Lifesciences Pvt. Ltd. Olmesartan Medoxomil Tablets IP 40 mg - M/s. Life Max Cancer Laboratories INFUSION SET-NV - M/s. Medivision Healthcare Telmisartan Tablets IP 40 mg - M/s. Life Max Cancer Laboratories Alprazolam Tablets IP 0.25 mg (Erazol-0.25 Tablets) - M/s. Elikem Pharmaceuticals Pvt. Ltd. Glimepiride Tablets IP (2 mg) - M/s. Mascot Health Series Pvt. Ltd. Calcium and Vitamin D3 Tablets IP - M/s. Unicure India Ltd. Metronidazole Tablets IP 400mg - M/s. Hindustan Antibiotics Ltd. Paziva -40 - M/s. Gnosis Pharmaceuticals Pvt. Ltd. Pantomed -40 - Digital Vision 176 Cefixime Oral Suspension IP (Dry Syrup) - Nestor Pharmaceuticals Ltd. Moxymed CV - Alexa Pharmaceuticals Frusemide Injection IP 20 mg - Nestor Pharmaceuticals Ltd. Kudajarishtam - Bala Herbals Tab Nodosis - Steadfast Medishield Pvt. Ltd. Haridrakhanda - Bhaskara Vilasam Vaidyasala Pantoprazole Inj. BP 40 mg - Kerala Medical Services Corporation Ltd. Yogaraja Guggulu - Bhaskara Vilasam Vaidyasala PANCEF-OF - Aglomed Ltd.

Drug Approval

19 Jul 2024

·www.outsourcing-pharma.com

Avista and Hamilton Lane Join Forces to Propel Growth and Innovation at Cosette Pharmaceuticals

The companies will jointly control Cosette, with a focus on accelerating innovation and growth. Since Avista's initial investment in Cosette in December 2018, Cosette has launched new products through research and development efforts, acquisitions, and licensing deals. This includes the acquisition of Ambien and Ambien CR in the United States from Sanofi US. The company reports that these initiatives have led to significant EBITDA growth and free cash flow generation, positioning Cosette for future opportunities. Apurva Saraf, president and CEO of Cosette, said: “This partnership is a testament to the remarkable transformation our business has achieved over the past four years, driven by an unwavering commitment to strategic business development and operational excellence. I am immensely proud of the entire Cosette team for their dedication in delivering this robust growth. “We have successfully diversified our portfolio with branded products such as Clomid, Ambien, and Benicar, along with innovative, patent-protected drugs like Vyleesi and Intrarosa. With our strong R&D and business development pipeline, we are well positioned to drive substantial growth in partnership with Avista and Hamilton Lane." Financial strength and future opportunities for Cosette Pharmaceuticals The companies indicate that this transaction will enhance Cosette's balance sheet and support growth through investments in R&D and strategic acquisitions. The goal is to build a durable, high-growth, branded pharmaceutical company. As part of the transaction, Cosette has also secured a new term loan financing with Hayfin Capital Management and a new revolving credit facility provided by UBS Investment Bank, Capital One, National Association, and Santander Corporate & Investment Bank, who acted as joint lead arrangers and joint bookrunners for the financing. googletag.cmd.push(function () { googletag.display('text-ad1'); }); David Burgstahler, managing partner and CEO of Avista, added: “We value Avista's long-term relationship with Hamilton Lane and look forward to collaborating with them as a strategic partner to drive growth and value at Cosette. Our collective expertise will prove invaluable as Cosette evaluates larger M&A opportunities as part of the company's growth strategy.” Cosette Pharmaceuticals has made significant contributions to the pharmaceutical industry, particularly in the realm of specialty pharmaceuticals. The company has a strong focus on developing and commercializing branded and generic products that address unmet medical needs. With a diverse portfolio that includes notable products, Cosette has demonstrated a commitment to innovation and patient care. It says its strategic approach to research and development, coupled with targeted acquisitions and licensing deals, has enabled them to introduce groundbreaking therapies and expand their market presence, positively impacting patient outcomes and advancing healthcare solutions.

AcquisitionLicense out/in

100 Deals associated with Olmesartan Medoxomil

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01204	Olmesartan Medoxomil	C09CA08	DB00275

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hypertension	United States	Cosette Pharmaceuticals, Inc.	25 Apr 2002

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metabolic Syndrome	Phase 3	Belgium	Daiichi Sankyo Europe GmbH	01 Aug 2008
Metabolic Syndrome	Phase 3	Germany	Daiichi Sankyo Europe GmbH	01 Aug 2008
Metabolic Syndrome	Phase 3	Italy	Daiichi Sankyo Europe GmbH	01 Aug 2008
Atrial Fibrillation	Phase 3	-	Daiichi Sankyo Co., Ltd.	01 Jan 2005
Diabetes Mellitus, Type 2	Phase 3	China	Daiichi Sankyo Co., Ltd.	01 Apr 2003
Diabetes Mellitus, Type 2	Phase 3	Japan	Daiichi Sankyo Co., Ltd.	01 Apr 2003
Diabetic Nephropathies	Phase 3	China	Daiichi Sankyo Co., Ltd.	01 Apr 2003
Diabetic Nephropathies	Phase 3	Japan	Daiichi Sankyo Co., Ltd.	01 Apr 2003
Kidney Failure, Chronic	Phase 3	China	Daiichi Sankyo Co., Ltd.	01 Apr 2003
Kidney Failure, Chronic	Phase 3	Japan	Daiichi Sankyo Co., Ltd.	01 Apr 2003

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05189015 (Pubmed \| Diabetol Metab Syndr)	Phase 4	Diabetes Mellitus, Type 2 \| Hypertension	80	Olmesartan 20 mg	ruyeyoeliw(ucmeoxmntn) = elmleeiyhg rveymfgtcq (mnbodsljsq ) View more	-	11 Mar 2023
				Amlodipine 5 mg	ruyeyoeliw(ucmeoxmntn) = yhozgynisb rveymfgtcq (mnbodsljsq ) View more
ESH2022	Not Applicable	Obesity, Abdominal	60	Olmesartan/Amlodipine combination therapy	fxinhumrsk(hjgjjllgwu) = wgdsnvpxiw zmrvvyxulr (sbszmrmroc, 82–105) View more	Positive	01 Jun 2022
FAMILY (ESH2021)	Not Applicable	Hypertension	-	Olmesartan combination therapy	qfabulcrzi(lzitktifqd) = awrrhiwaox cuoxdrvvah (wxrnxfnfer ) View more	Positive	01 Apr 2021
ESH2021	Not Applicable	Hypertension obese patients	60	Olmesartan and Amlodipine (20 mg/5 mg; 40 mg/10 mg)	yjijkukaxo(rndasujdfy) = pnqacxgybv fwtqrpuvfn (gulgneckip ) View more	Positive	01 Apr 2021
				Lisinopril and Amlodipine (10 mg/5 mg; 20 mg/5 mg; 20 mg/10 mg)	yjijkukaxo(rndasujdfy) = lzgcvxoiwe fwtqrpuvfn (gulgneckip ) View more
BLOOD PRESSURE CONTROL-RATES (ESH2021)	Not Applicable	Hypertension First line	80	Perindopril (ACE)	odzsduamjy(sgtkzisscy) = xkysqoawok pqdyxfeybq (kylygdciyo ) View more	Negative	01 Apr 2021
				Olmesartan (ARB)	odzsduamjy(sgtkzisscy) = vimzajdlxx pqdyxfeybq (kylygdciyo ) View more
ESC2020	Not Applicable	Diabetes Mellitus, Type 2 \| Hypertension angiotensin-(1-7)	76	ARB olmesartan	tkntqyazcu(iwefrmwchi) = eptsoqfdau ollmqxmltx (cvcfkxjbrx )	-	28 Aug 2020
				ACEi ramipril	tkntqyazcu(iwefrmwchi) = iizjqqyoqh ollmqxmltx (cvcfkxjbrx )
ISC2020	Not Applicable	Post-stroke Fatigue	36	Olmesartan/Azelnidipine combination	tqkahpgxst(dwnwvgdgsa) = dpuigkxwaq gicjnoybyo (hugurrgjye )	-	01 Feb 2020
				High-dose olmesartan	tqkahpgxst(dwnwvgdgsa) = txoioxmzlb gicjnoybyo (hugurrgjye )
OCTOPUS (ERA2019)	Not Applicable	-	461	Olmesartan	budhqakygm(dfhiqcovke) = dhumfgjrni lfkcowwabe (kbljcmrlzm )	Negative	13 Jun 2019
				Other antihypertensive medications	budhqakygm(dfhiqcovke) = tlwsjmhxdq lfkcowwabe (kbljcmrlzm )
SOAT STUDY (ESH2017)	Not Applicable	Hypertension	428	Olmesartan 20/5 mg	gjbqxosfmg(ulmslfkuxt) = shpomfcqvw gibdvfkevz (wpluoticha, 12.89) View more	Positive	01 Sep 2017
				Olmesartan 40/5 mg	gjbqxosfmg(ulmslfkuxt) = vctaacvbsg gibdvfkevz (wpluoticha, 10.87) View more
[PP.36.05] (ESH2016)	Not Applicable	Hypertension miR145 \| miR221 \| miR222	-	Losartan 100 mg	dccjcolavq(rmkobctflf) = zddvmhtrmf krjxhjtexy (wycxzyuwqx ) View more	Positive	01 Sep 2016